• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Talanta . A multi-target lateral flow immunoassay enabling the specific and sensitive detection of total antibodies to SARS COV-2

tetano

Editor, Senior Moderator
Talanta


. 2021 Feb 1;223(Pt 1):121737.
doi: 10.1016/j.talanta.2020.121737. Epub 2020 Oct 5.
A multi-target lateral flow immunoassay enabling the specific and sensitive detection of total antibodies to SARS COV-2


Simone Cavalera[SUP] 1 [/SUP], Barbara Colitti[SUP] 2 [/SUP], Sergio Rosati[SUP] 2 [/SUP], Gianmarco Ferrara[SUP] 3 [/SUP], Luigi Bertolotti[SUP] 2 [/SUP], Chiara Nogarol[SUP] 4 [/SUP], Cristina Guiotto[SUP] 5 [/SUP], Celeste Cagnazzo[SUP] 6 [/SUP], Marco Denina[SUP] 7 [/SUP], Franca Fagioli[SUP] 6 [/SUP], Fabio Di Nardo[SUP] 1 [/SUP], Matteo Chiarello[SUP] 1 [/SUP], Claudio Baggiani[SUP] 1 [/SUP], Laura Anfossi[SUP] 8 [/SUP]



Affiliations
Free PMC article

Abstract

A rapid test for detecting total immunoglobulins directed towards the nucleocapsid protein (N) of severe acute syndrome coronavirus 2 (SARS CoV-2) was developed, based on a multi-target lateral flow immunoassay comprising two test lines. Both test lines bound to several classes of immunoglobulins (G, M, and A). Specific anti-SARS immunoglobulins were revealed by a colorimetric probe formed by N and gold nanoparticles. Targeting the total antibodies response to infection enabled achieving 100% diagnostic specificity (95.75-100, C.I. 95%, n = 85 healthy and with other infections individuals) and 94.6% sensitivity (84.9-98.9, C.I. 95%, n = 62 SARS CoV-2 infected subjects) as early as 7 days post confirmation of positivity. Agreeing results with a reference serological ELISA were achieved, except for the earlier detection capability of the rapid test. Follow up of the three seroconverting patients endorsed the hypothesis of the random rise of the different immunoglobulins and strengthened the 'total antibodies' approach for the trustworthy detection of serological response to SARS CoV-2 infection.

Keywords: Immunochromatographic strip test; Optical biosensor; Rapid test; SARS CoV-2
 
Back
Top Bottom